GT Apeiron Therapeutics
Dr. Minghua Wang is the Director of AIDD at Apeiron Therapeutics. He has over 15 years of small molecule drug discovery experience. Minghua has worked at different biotech companies, applying computational chemistry to drug design in many drug targets, spanning from enzymes to receptors. Most recently he worked on membrane protein targets in neuroscience diseases at Cerevel Therapeutics. Minghua completed his Ph.D. at Chinese Academy of Sciences and is an author on over 25 patents and publications.
This person is not in any offices
GT Apeiron Therapeutics
Apeiron Therapeutics intends to develop breakthrough investigational medicines by harnessing the power of artificial intelligence which drastically increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials.